



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)

Anti-Dxd [12G9-2] Standard Size Ab04094-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgG1, Fc Silent™, Kappa

Clone Number: 12G9-2

Alternative Name(s) of Target: Exatecan derivative; Camptothecin analog

UniProt Accession Number of Target Protein:

Published Application(s): ELISA

Published Species Reactivity: Species independent

Immunogen: The original antibody was generated by immunizing BALB/c mice with Dxd-KLH conjugate.

Specificity: This antibody binds Dxd, an anti-cancer alkaloid camptothecin analog, which is a potent DNA topoisomerase I (TOP1) inhibitor. By forming a stable ternary complex with TOP1 and DNA, it arrests the cell cycle to S phase, thereby preventing DNA replication and causing cell death. DxD is used for the generation of antibody-drug conjugates for targeted delivery of toxic materials to cancerous cells. A HER2 targeting -DxD drug conjugate (DS-8201a) shows potent antitumor activity in HER2-positive models

Application Notes: The binding reactivity of this antibody towards Dxd-KLH and Dxd-BSA conjugates was determined using ELISA. This antibody is capable of binding antibody-drug conjugates ADC-8201 and ADC029 in a competitive ELISA, wherein the antibody was trastuzumab. The binding affinity of this antibody towards Dxd-BSA was determined using surface plasmon resonance (SPR) and it was reported to be $K_d = 3.38\text{nM}$ (CN115677857).

Antibody First Published in: [PMID:](#)

Note on publication:

Product Form

Size: 100 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -

20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.